Navi Mumbai, Maharashtra India (PressExposure) March 19, 2008 -- At present, the pharmaceutical prescription market to treat GI disorders market is valued at just over $20 billion, reflecting that it is one of the largest and most important therapeutic areas in the pharmaceutical industry. It has just produced a business intelligence report, Gastrointestinal Disorders 2007-2012, which addresses the state of this market, and assesses how it will develop in the future. Are you involved in this market area? Will the future of this market affect your business?
AstraZeneca's Nexium is currently the most successful GI drug available in the market, based on sales revenues totaling more than $6 billion. What is the future for Nexium? How will its impact shape the GI market? Will other GI drugs reach blockbuster status? If so, which ones?
Another example of change in the GI market is the withdrawal of Novartis's from the US market, due to safety and efficacy issues. What effects will this have on the other GI drugs? How will this affect the overall GI market? What does the future hold for Novartis and Zelnorm?
It's World Gastrointestinal Disorders report includes three major classes of product which It believes will extensively occupy the GI market. These are:
Proton Pump Inhibitors (PPIs) Histamine H2 Receptor Antagonists Other Leading GI agents Which new drugs will be marketed? Which drugs will have the most impact on the market? Most importantly, what are the future prospects of the GI market?
For more information kindly visit: [http://www.bharatbook.com/detail.asp?id=46979]